Levi Rafael, Ozçakir Hasan Tayfun, Adakan Saban, Göker Ege Nazan Tavmergen, Tavmergen Erol
Ege University Family Planning Infertility Research and Treatment Center, Izmir, Turkey.
J Obstet Gynaecol Res. 2003 Aug;29(4):257-61. doi: 10.1046/j.1341-8076.2003.00110.x.
In the present study, we examined the outcome of assisted reproductive technology cycles in patients with or without baseline ovarian cysts following gonadotrophin-releasing hormone analogs administration.
Three-hundred and fifty-six patients who had undergone assisted reproductive technology treatment were enrolled in the study. The patients, all of who had undergone cyst aspiration prior to ovarian stimulation, were grouped into two groups according to the absence or presence of ovarian cysts. These two groups were compared on the basis of the clinical pregnancy rates, the baseline E2 levels, the total follicle stimulating hormone ampules used, the total number of days of induction, the maximum E2 levels, the number of oocytes retrieved, the fertilization rates and the number of embryos available for transfer per controlled ovarian hyperstimulation cycle.
The number of ampules used for induction was significantly higher in the cyst group 37.2 +/- 13.0, 32.1 +/- 11.7, respectively, (P = 0.001). The number of total induction days was also longer in the cyst group 9.7 +/- 2.2, 8.9 +/- 1.6, respectively, (P = 0.001). There was no difference between the mean E2 levels measured on the human chorionic gonadotropin administration days (P = 0.339). There was also no difference in terms of the number of oocyte retrieved (P = 0.846). The number of embryos transferred did not differ statistically between the groups (P = 0.233). Finally, there was no significant difference between the groups according to the clinical pregnancy rates 25.3%, 30.7%, respectively, (P = 0.218).
Baseline ovarian cysts have a negative impact on the quality of ovarian hyperstimulation procedure; however, they have no negative effect on the pregnancy rates in IVF cycles.
在本研究中,我们检查了给予促性腺激素释放激素类似物后有或无基线卵巢囊肿的患者辅助生殖技术周期的结果。
356例接受辅助生殖技术治疗的患者纳入本研究。所有患者在卵巢刺激前均接受了囊肿抽吸,根据是否存在卵巢囊肿分为两组。比较两组的临床妊娠率、基线雌二醇水平、使用的促卵泡生成素安瓿总数、诱导总天数、最高雌二醇水平、获取的卵母细胞数、受精率以及每个控制性卵巢过度刺激周期可用于移植的胚胎数。
囊肿组诱导使用的安瓿数显著更高(分别为37.2±13.0、32.1±11.7,P = 0.001)。囊肿组的总诱导天数也更长(分别为9.7±2.2、8.9±1.6,P = 0.001)。在人绒毛膜促性腺激素给药日测量的平均雌二醇水平之间无差异(P = 0.339)。获取的卵母细胞数也无差异(P = 0.846)。两组之间移植的胚胎数在统计学上无差异(P = 0.233)。最后,根据临床妊娠率,两组之间无显著差异(分别为25.3%、30.7%,P = 0.218)。
基线卵巢囊肿对卵巢过度刺激程序的质量有负面影响;然而,它们对体外受精周期的妊娠率没有负面影响。